151 related articles for article (PubMed ID: 11900880)
1. TP53: a key gene in human cancer.
Guimaraes DP; Hainaut P
Biochimie; 2002 Jan; 84(1):83-93. PubMed ID: 11900880
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
4. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
5. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
7. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
Ishii N; Tada M; Hamou MF; Janzer RC; Meagher-Villemure K; Wiestler OD; Tribolet N; Van Meir EG
Oncogene; 1999 Oct; 18(43):5870-8. PubMed ID: 10557074
[TBL] [Abstract][Full Text] [Related]
8. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
10. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
11. Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer.
Güran S; Pak I
Cancer Genet Cytogenet; 1999 Mar; 109(2):108-13. PubMed ID: 10087941
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
13. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
16. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
17. TP53: an oncogene in disguise.
Soussi T; Wiman KG
Cell Death Differ; 2015 Aug; 22(8):1239-49. PubMed ID: 26024390
[TBL] [Abstract][Full Text] [Related]
18. TP53 cancerous mutations exhibit selection for translation efficiency.
Waldman YY; Tuller T; Sharan R; Ruppin E
Cancer Res; 2009 Nov; 69(22):8807-13. PubMed ID: 19887606
[TBL] [Abstract][Full Text] [Related]
19. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations in workers exposed to occupational carcinogens.
Vähäkangas K
Hum Mutat; 2003 Mar; 21(3):240-51. PubMed ID: 12619109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]